BCAL Diagnostics Ltd (asx:BDX) Share Price

Company Profile

Business description
BCAL Diagnostics Ltd is an Australian health care company engaged in early cancer detection. BCAL launched its first test, BREASTESTplus, as a rule-out test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTESTplus is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women. BCAL holds an exclusive license with ClearNote Health Inc., a U.S-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.
Contact
50 Clarence Street
Suite 506, Level 5
SydneyNSW2000
AUS
T: +61 290787671
https://www.bcaldiagnostics.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2027
Employees

Recommended

Short term headwinds mask long term value opportunity.

Brian Han | 25 August 2026

Geopolitical tensions drive strong profit and dividends for oil refiner.

Mark Taylor | 25 August 2026

Higher costs weigh on profits but stronger sales trends support long term outlook.

Johannes Faul, CFA | 25 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,352.80	40.50	-0.43%
CAC 40	8,439.20	13.81	-0.16%
DAX 40	26,266.14	159.54	0.61%
Dow JONES (US)	53,577.40	160.24	0.30%
FTSE 100	10,886.16	31.84	0.29%
HKSE	25,714.89	203.79	0.80%
NASDAQ	26,151.30	171.11	0.66%
Nikkei 225	66,227.55	371.12	0.56%
NZX 50 Index	14,034.21	41.49	0.30%
S&P 500	7,677.28	24.42	0.32%
S&P/ASX 200	9,143.60	40.10	-0.44%
SSE Composite Index	3,918.95	29.51	0.76%